Uveitis
Drug research and approvals for uveitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 45 studies of uveitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 5 approved and 8 open orphan designations naming it.
- Recruiting worldwide: 45
- Trials authorized in Canada: 3
- FDA orphan approvals: 5
- EU medicines: 0
Recruiting now
Newest start dates first, of 45 recruiting on ClinicalTrials.gov ↗- Gryrotonic Training in Behcet-diseased Elders With Breast CancerNCT07929116 · Not applicable · Cairo University · starts Nov 30, 2026
- A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)NCT07861074 · Phase 2 · Merck Sharp & Dohme LLC · starts Nov 4, 2026
- PANDA-ASOCT: Paediatric Anterior Uveitis Detection With Automated Image Analysis Using ASOCTNCT07813598 · Not reported · Sheffield Children's NHS Foundation Trust · starts Sep 9, 2026
- Ocular Fluid Work-up in Presumed Trematode Induced Granulomatous UveitisNCT07885137 · Not reported · Kasr El Aini Hospital · starts Sep 1, 2026
- A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With…NCT07663331 · Phase 4 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · starts Jul 14, 2026
- A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.NCT07547995 · Phase 2 · Changchun GeneScience Pharmaceutical Co., Ltd. · starts Jun 29, 2026
- Diet Restiction in Subjects With Behcet Disease and Complaint of TinnitusNCT07702149 · Not applicable · Cairo University · starts Jun 4, 2026
- Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet DiseaseNCT07702123 · Not applicable · Cairo University · starts Jun 2, 2026
- Behcet Disease Patients With Pulmonary Endoarterectomy: Outcomes of Program of Inspiratory Msucle TrianingNCT07662603 · Not applicable · Cairo University · starts May 6, 2026
- A Study of Uveitis in Children <18 Years of AgeNCT07518134 · Not reported · Jaeb Center for Health Research · starts Apr 14, 2026
Drug pipeline
5 approved, 11 in phase 3, 16 in phase 2, 8 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Adalimumab, Fluocinolone acetonide, Methylprednisolone acetate, Prednisolone phosphoric acid, Dexamethasone
- Prednisone
- Phase 3 Glucocorticoid receptor agonist
- Secukinumab
- Phase 3 Interleukin 17A inhibitor
- Methotrexate
- Phase 3 Dihydrofolate reductase inhibitor
- Gevokizumab
- Phase 3 Interleukin-1 beta negative allosteric modulator
- Mycophenolate mofetil
- Phase 3 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Baricitinib
- Phase 3 Tyrosine-protein kinase JAK1 inhibitor
- Difluprednate
- Phase 3 Glucocorticoid receptor agonist
- Voclosporin
- Phase 3 Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
- Bevacizumab
- Phase 3 Vascular endothelial growth factor A inhibitor
- Triamcinolone acetonide
- Phase 3 Glucocorticoid receptor agonist
- Prednisolone acetate
- Phase 3 Glucocorticoid receptor agonist
- Daclizumab
- Phase 2 Interleukin-2 receptor inhibitor
- Tocilizumab
- Phase 2 Interleukin-6 receptor alpha subunit inhibitor
- Simvastatin
- Phase 2 HMG-CoA reductase inhibitor
- Ustekinumab
- Phase 2 Interleukin-12 inhibitor
- Izokibep
- Phase 2 Interleukin 17A inhibitor
- Everolimus
- Phase 2 FK506-binding protein 1A inhibitor
- Leflunomide
- Phase 2 Dihydroorotate dehydrogenase inhibitor
- Basiliximab
- Phase 2 Interleukin-2 receptor inhibitor
- Sarilumab
- Phase 2 Interleukin-6 receptor alpha subunit antagonist
- Anakinra
- Phase 2 Interleukin-1 receptor antagonist
- Corticotropin
- Phase 2 Melanocortin receptor 2 agonist
- Abatacept
- Phase 2 T-lymphocyte activation antigen CD86 inhibitor
- Fingolimod
- Phase 2 Sphingosine 1-phosphate receptor agonist
- Filgotinib
- Phase 2 Tyrosine-protein kinase JAK1 inhibitor
- Folic acid
- Phase 2
- Leucovorin
- Phase 2
- Cyclosporine
- Phase 1 Cyclophilin A modulator
- Ocriplasmin
- Phase 1 Fibronectin proteolytic enzyme
- Interferon GAMMA-1B
- Phase 1 Interferon gamma receptor agonist
Showing the 30 furthest along of 35 in trials.
How its trials ended
337 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 94 whose ending is known, 39% met their primary endpoint, 0% missed it and 61% stopped early.
- Completed, result not reported14543%
- Ongoing5015%
- Status unknown4814%
- Met its primary endpoint3711%
- Stopped: other or unclear3510%
- Stopped: enrollment or feasibility93%
- Stopped: sponsor or business decision72%
- Stopped: lack of efficacy51%
- Stopped: safety10%
Trials authorized in Canada
Newest first; search them all in Canada trials| Sep 3, 2026 | A phase 2b, randomized, double-masked, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with active noninfectious…MK-7240 (tulisokibart) / Prednisone | Merck & Co. (MSD) | Pending |
| Nov 1, 2019 | Adalimumab vs conventional immunosuppression for uveitis (ADVISE) trialHumira (adalimumab) / Imuran (azathioprine) / Neoral (cyclosporine) /… | Johns Hopkins Bloomberg School of Public Health | Pending |
| Jul 25, 2013 | A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate,…Gevokizumab | Servier | Ongoing |
FDA orphan designations
Approved first, then open designations, newest first| Sep 28, 2018 | HumiraTreatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older | AbbVie, Inc. | Approved |
| Jun 30, 2016 | HumiraIndicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients | AbbVie, Inc. | Approved |
| Jun 13, 2012 | DurezolTreatment of endogenous anterior uveitis | Alcon Pharmaceuticals. Ltd. | Approved |
| Sep 24, 2010 | OzurdexFor treatment of non-infectious uveitis affecting the posterior segment of the eye | Allergan | Approved |
| Apr 8, 2005 | RetisertTreatment of chronic non-infectious uveitis affecting the posterior segment of the eye | Bausch & Lomb Pharmaceuticals, Inc. | Approved |
| Oct 4, 2023 | MethotrexateTreatment of non-infectious intermediate, posterior, or pan uveitis or chronic non-infectious anterior uveitis | Nordic Group B.V. | Designated |
| Jun 22, 2022 | AAV2.adalimumabTreatment of non-infectious intermediate, posterior, or panuveitis or chronic non-infectious anterior uveitis | Kriya Therapeutics, Inc. | Designated |
| Dec 7, 2021 | TacrolimusTreatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitis | BioNanoSim Ltd. | Designated |
| Jun 3, 2019 | Ac-Nle-cyclo-(Glu-His-D-Phe-Arg-Dap)-Trp-NH2Treatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitis | Palatin Technologies, Inc. | Designated |
| Nov 4, 2011 | SirolimusTreatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and… | Santen Inc. | Designated |
| Dec 20, 2006 | Cyclo…Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis | Lux Biosciences, Inc. | Designated |
| Jan 16, 2003 | Human Anti-tumor Necrosis factor alpha monoclonal antibodyTreatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology… | Centocor, Inc. | Designated |
| Oct 8, 1992 | Ai-rsaTreatment of autoimmune uveitis. | AutoImmune, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA